Work

Bimekizumab efficacy through one year in patients with moderate to severe plaque psoriasis in subgroups defined by prior biologic treatment: Pooled results from four phase 3/3b trials

Year: 2022

Type: article

Abstract: N/A

Source: SKIN The Journal of Cutaneous Medicine

DOI: 10.25251/skin.6.supp.64

Authors: Mark Lebwohl, April W Armstrong, Joseph F Merola, Alice B Gottlieb, Leah Davis, Braulio Gomez, Susanne Wiegratz, Nancy Cross, Bruce Strober

Institutions: Icahn School of Medicine at Mount Sinai, University of Southern California, Brigham and Women's Hospital, Harvard University, UCB Pharma (Belgium), Yale University

Language: English

Topic: Psoriasis: Treatment and Pathogenesis

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: diamond

Funder: UCB Pharma

OpenAlex ID: W4309317003

FWCI: 0.077

Cites:

Cited by: 1

Related to: 10